Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes

Firdapse, or amifampridine phosphate, is a medication currently approved for Lambert-Eaton myasthenic syndrome, or LEMS. However, Catalyst Pharmaceuticals has been working to evaluate if it can aid other neurological and…

Continue Reading Catalyst is Meeting with the FDA to Discuss the Future of Firdapse for Congenital Myasthenic Syndromes
Study Highlights Long Term Benefits of Thymectomy Surgery for Myasthenia Gravis Patients
skeeze / Pixabay

Study Highlights Long Term Benefits of Thymectomy Surgery for Myasthenia Gravis Patients

According to a story from EurekAlert!, a recent study revealed that the surgical removal of the thymus gland, known as a thymectomy, was able to provide long-term benefits for patients…

Continue Reading Study Highlights Long Term Benefits of Thymectomy Surgery for Myasthenia Gravis Patients

Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online

Myasthenia Gravis (MG) is a progressive autoimmune disorder which results in the weakening of muscles. Most people with the condition are able to manage their symptoms with treatment and have…

Continue Reading Positive Results From a Phase IIb Trial of Firdapse for MuSK Myasthenia Gravis Published Online
Global Phase 3 Trial For Experimental Myasthenia Gravis Treatment to Begin Before The End of The Year
mwooten / Pixabay

Global Phase 3 Trial For Experimental Myasthenia Gravis Treatment to Begin Before The End of The Year

According to a story from Euroinvestor, the biotechnology company argenx recently announced that it has gotten correspondence from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in regards to the design…

Continue Reading Global Phase 3 Trial For Experimental Myasthenia Gravis Treatment to Begin Before The End of The Year
Check out these Invaluable Resources for Myasthenia Gravis Awareness Month!
3dman_eu / Pixabay

Check out these Invaluable Resources for Myasthenia Gravis Awareness Month!

June is here - and so is Myasthenia Gravis Awareness Month! What is Myasthenia Gravis you say? Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by weakness and rapid fatigue of any of…

Continue Reading Check out these Invaluable Resources for Myasthenia Gravis Awareness Month!

Hopeful News for the European Refractory Generalized Myasthenia Gravis Community

This month, Soliris®, a treatment produced by Alexion Pharmaceuticals, Inc. was approved by the European Commission for the treatment of Refractory Generalized Myasthenia Gravis (gMG). Myasthenia gravis (MG) is a…

Continue Reading Hopeful News for the European Refractory Generalized Myasthenia Gravis Community